Mammoth Biosciences Stock

mammoth.bioHealthcareFounded: 2017Funding to Date: $257.38MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, is enabling the full potential of its platform to improve lives by reading and writing the code of life. The company was founded by Trevor Martin Ph.D., Janice Chen Ph.D., Lucas Harrington, and Jennifer Doudna Ph.D. in 2017 and is headquartered in Brisbane, CA.

Register for Details

For more details on financing and valuation for Mammoth Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Mammoth Biosciences.

Register Today


Management Team

Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Ted Tisch
Chief Agility Officer

Board Members

Dean Minor MD
Board Member
Maneesh Jain Ph.D
Board Member
Ursheet Parikh
Mayfield (Private Equity)
Victor Tong Jr.
Decheng Capital

Other companies like Mammoth Biosciences in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.
San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …